All posts of Dr. Joseph Connors

Ibrutinib Treatment in Waldenström Macroglobulinemia: The iNNOVATE Study

Oral presentation by Dr. Christian Buske In Canada, symptomatic patients with Waldenström’s macroglobulinemia (WM) are treated with a variety of initial regimens including bendamustine with or without rituximab, chlorambucil with or without rituximab, and rituximab alone. Relapsed patients are either re-treated with one of those regimens or occasionally with ibrutinib. However, access to ibrutinib is […]

Ibrutinib Alone or with Rituximab in Untreated Older Patients with CLL

Oral presentation by Dr. Jennifer A. Woyach In Canada, treatment-naïve symptomatic elderly (age >65 years) patients with chronic lymphocytic leukemia (CLL), but without evidence of deletion 17p (del[17p]), are treated with a variety of initial regimens including bendamustine with or without rituximab, chlorambucil with or without rituximab, or obinutuzumab and rituximab alone. The Alliance North […]

PET-Guided Radiation Therapy in Patients with Advanced-Stage DLBCL Treated with R-CHOP in British Columbia

Oral presentation by Dr. Ciara Freeman Many patients with advanced-stage, diffuse large B-cell lymphoma (DLBCL) reach the end of their planned multi-agent chemotherapy with persistent abnormal masses of indeterminate significance. Functional imaging with fluorodeoxyglucose positron emission tomography (PET) offers the possibility to identify complete responders who require no additional treatment, and incomplete responders who may […]

Ibrutinib Plus FCR As Front-Line Therapy for Younger CLL Patients

Oral presentation by Dr. Matthew S. Davids Although fludarabine, cyclophosphamide, and rituximab (FCR) has emerged as one of the very best treatment regimens for symptomatic chronic lymphocytic leukemia (CLL), the leukemia re-emerges and again threatens the patient all too often. This is especially true for those patients presenting with unmutated immunoglobulin heavy-chain variable region gene […]

Commentary on Late-Breaking Results from the BMT CTN 0702 – StaMINA Trial

Investigators continue to search for the best initial treatment for patients with newly diagnosed plasma cell myeloma. Several studies have previously demonstrated that a tandem transplant approach (serial treatment with two rounds of high-dose chemotherapy supported by autologous stem cell transplant) or transplant followed by maintenance immunomodulatory treatment produce results that are among the most […]

Pembrolizumab in Hodgkin Lymphoma: Insights from the Keynote-013 and Keynote-087

The anti-programmed death-ligand 1 immune checkpoint inhibitors continue to generate exciting results across all of oncology, especially in patients with Hodgkin lymphoma (HL). At ASH 2016, we watched two presentations focused on the effectiveness and toxicity of pembrolizumab in relapsed or refractory (R/R) HL. Dr. Moskowitz described the phase II Keynote-087 trial results using a […]

Insights on Ibrutinib Treatment for Patients with CLL/SLL

Abstracts #233 and #234 presented at ASH 2016 are best appreciated together. Both address the long-term outcomes using ibrutinib for chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL). In the first abstract, Dr. Susan O’Brien describes the long-term follow-up of patients treated with ibrutinib. In the second abstract, Dr. Paul Barr describes the outcome on […]